Clinical laboratory news of the day – Highly accurate blood test based on artificial intelligence for early detection of colorectal cancer – molecular diagnostics

Highly accurate blood test based on artificial intelligence for early detection of colorectal cancer

Author: LabMedica Editorial in Spanish
Updated February 08, 2024

Colorectal cancer (CRC) is the third most common cancer in men and the second most common in women worldwide, accounting for 10% of all cancer cases; the most developed regions account for 55% of these cases. It is also the second leading cause of cancer deaths in the world, accounting for 9.4% of all cancer deaths. Although CRC screening methods such as colonoscopy and stool testing are available, they have limitations. There is an urgent need for a more effective blood-based colorectal cancer screening tool that can detect cancer early, accurately and easily at different stages. Now, an innovative blood test for early detection has demonstrated high potential and excellent accuracy in diagnosing CRC.

The PreveCol blood test for colorectal cancer screening, developed by Amadix (Madrid, Spain), combines an artificial intelligence (AI)-based algorithm with plasma biomarker level analysis for the early detection of colorectal cancer and advanced adenoma (AA). PreveCol is designed for the early detection of blood biomarkers associated with colorectal neoplasia and is suitable for screening adults aged 45 years and older without obvious symptoms. It demonstrates high accuracy in detecting colorectal cancer and is particularly effective in detecting advanced adenomas, which are precancerous lesions. A positive PreveCol result suggests the possible presence of colorectal cancer and/or advanced precancerous lesions, requiring subsequent diagnostic colonoscopy. This blood test for early detection of CRC is non-invasive, quick and does not require sedation.

Image: PreveCol Cancer Blood Test Receives Breakthrough Device Designation from US FDA (Photo courtesy of Amadix)

Early detection and removal of precancerous lesions is critical to preventing the development of CRC, and early detection of cancer significantly improves patient outcomes. These factors highlight the importance of CRC screening as a global health priority. The noninvasive nature of PreveCol, requiring only a blood test, may improve adherence to colorectal cancer screening recommendations. This test has received breakthrough device status from the US Food and Drug Administration (FDA), making it the first European company to receive such recognition for the early detection of CRC. PreveCol showed potential for significant benefit to patients and demonstrated improved diagnostic performance compared with existing approved CRC screening tests in the United States.

“Receiving this recognition from the FDA is an important milestone for our company. It motivates us to continue working to bring PreveCol to American patients as quickly as possible,” said Rocio Arroyo, CEO of Amadix. “We will continue to prevent colorectal cancer and the complications caused by current treatments.”